SMAD2 and ovarian carcinoma: Given that NEDD4L is the principle ubiquitin ligase targeting activated Smad2/3 to constrain the signaling capacity of the TGF-β pathway (14), it is likely that NEDD4L impacts the progression of ovarian cancer through compromising the responsiveness of cancer cells to TGF-β stimulation.